[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intestinal-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intestinal-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,81,109,136,161,187,212,239],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100643532","gut-leakage-in-dengue-100643532",false,"NCT07602920","Gut Leakage' in Dengue","Gut Leakage and Sonographic Abdominal Changes in Hospitalized Dengue Patients: an Observational Study","GLiD","Inclusion Criteria:\n\nDengue participants\n\n* Participant\u002F legally authorised representative willing and able to give informed consent for participation in the study.\n* Male or Female, adults ≥18 years\n* Diagnosed as a case of Dengue on the basis of clinical features and positive NS1 antigen and\u002For IgM dengue antibody\n* Hospitalized in medicine or dengue ward in Chittagong Medical College Hospital.\n* Enrolled within 24 hours of hospitalization.\n\nHealthy participants\n\n* Participant\u002F legally authorised representative willing and able to give informed consent for participation in the study.\n* Male or Female, adults ≥18 years\n* Clinically healthy with no acute or chronic illness\n* Attendant of a dengue patient (not a patient)\n\nExclusion Criteria:\n\nDengue participants\n\n* Unable to provide consent or participate in follow-up procedures\n* Known chronic gastrointestinal (GI) disease affecting intestinal permeability (IBD, celiac disease), chronic liver disease, active chronic diarrhoea, short bowel loop syndrome, recent (\\\u003C3 months) major GI surgery.\n* Immunosuppression (for example chemotherapy, high-dose steroids), advanced chronic kidney disease, decompensated heart failure.\n* Drugs that can alter the level of biomarkers in blood like metformin, statin, probiotics, steroid within last 48 hours of hospitalization.\n* Pregnancy\n\nHealthy participants\n\n* Unable to provide consent\n* Known chronic gastrointestinal (GI) disease affecting intestinal permeability (IBD, celiac disease), chronic liver disease, active chronic diarrhoea, short bowel loop syndrome, recent (\\\u003C3 months) major GI surgery.\n* Immunosuppression (for example chemotherapy, high-dose steroids), advanced chronic kidney disease, decompensated heart failure.\n* Drugs that can alter the level of biomarkers in blood like metformin, statin, probiotics, steroid within last 48 hours of hospitalization.\n* Pregnancy\n* History of current or recent dengue or other arbo viral infection",true,"ALL","18 Years",{"count":21,"type":22},190,"ESTIMATED","OBSERVATIONAL","Dengue infections are imposing an increasing global burden of disease, particularly in tropical countries such as Bangladesh. The World Health Organization (WHO) has identified Dengue virus as a priority pathogen for the development of medical counter measures because of the high risk of it causing a Public Health Emergency of Intenational Concern (PHEIC). Warning signs for severe dengue, associated with mortality, include gastrointestinal features including abdominal pain, vomiting, and diarrhoea. Multiple alterations may occur in in the gastrointestinal tract that could lead to damaging of the gastrointestinal wall and gut leakage, the translocation of gut metabolites into the bloodstream. Study team hypothesize that gut leakage initiates inflammatory processes underlying the further development of severe dengue, including features associated with plasma leakage.\n\nThis study aims to investigate intestinal barrier dysfunction (gut leakage) in dengue infection by detecting the translocation of gut-derived bacteria and their products (Lipopolysaccharides, LPS binding protein, sCD14, I-Fatty Acid Binding Protein) into the bloodstream. Study team will recruit hospitalized adult dengue patients (18 years and older) presenting with warning signs or severe disease in a tertiary care public hospital at Chattogram, Bangladesh. Circulating biomarkers indicative of gut permeability and microbial translocation will be measured to assess their presence and association with disease severity.\n\nAbdominal ultrasonography will be performed to characterize gastrointestinal alterations and determine their correlation with biochemical markers of gut leakage and clinical severity. In addition, study team will analyze the gut bacteriome from stool\u002F rectal swab of these patients to explore whether dengue infection induces compositional changes in intestinal microbiota and whether such alterations are linked to gut leakage or disease progression.",[26,27,28,29,30,31],"Dengue","Dengue Hemorrhagic Fever","Intestinal Disease","Ascites","Dengue With Warning Signs","Gut Microbiome","NOT_YET_RECRUITING","2026-06-08",{"date":35,"type":36},"2026-06-10","ACTUAL",{"date":38,"type":22},"2026-07-01",{"date":40,"type":22},"2028-01-31",{"name":42,"class":43},"University of Oxford","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":44},"100536954","phase-4-evaluation-of-efficacy-of-skl-pro-powder-on-symptoms-of-irritable-bowel-syndrome-100536954","NCT06271538","Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome","A Randomized Double-Blind Placebo-controlled Clinical Trial on the Efficacy of Skål Pro (Lactobacillus Plantarum 299 and Galacto-oligosaccharides) in Improving Severity of Symptoms, Stool Forms, Quality of Life and Psychological Dysfunction in Patients With Irritable Bowel Syndrome (IBS)","Inclusion Criteria:\n\n* IBS diagnosed using the Rome IV criteria\n* Age above 18 years old and any gender\n* Any subtypes of IBS (diarrhea, constipation or mixed)\n\nExclusion Criteria:\n\n* Presence of red flag symptoms (weight loss, anemia, night symptoms, abdominal mass, strong family history of cancer)\n* Was prescribed antibiotic (s) within the past one month\n* Medical conditions that contraindicate probiotic use including severe sepsis and pregnancy\n* Presence of bowel malignancy\n* Diagnosis of bowel infection within the past one month\n* Previous abdominal surgeries\n* Patients with overt psychiatric illnesses including schizophrenia and manic disorders\n* A history of allergy to probiotic\n* Was prescribed probiotic (s) within the past one month\n* Was previously prescribed probiotic Skal Pro™ (LP299V™)",{"count":53,"type":22},60,"INTERVENTIONAL",[56],"PHASE4","The objective of this randomized, double-blind, placebo-controlled study is to evaluate the effectiveness of Skal Pro in alleviating symptoms, enhancing stool consistency, improving quality of life, and addressing psychological distress in individuals diagnosed with irritable bowel syndrome (IBS), as compared to those who receive no intervention.",[59,60,61,28,62,63,64,65],"Irritable Bowel Syndrome","Gastrointestinal Diseases","Colonic Diseases, Functional","Digestive System Disease","Pathologic Processes","Colonic Disease","Disease",[67,68,69],"probiotic","Lactobacillus plantarum 299v","randomized controlled study","RECRUITING","2026-05-11",{"date":73,"type":36},"2026-05-12",{"date":75,"type":36},"2024-10-17",{"date":77,"type":22},"2026-06-30",{"name":79,"class":80},"EP Plus Group Sdn Bhd","INDUSTRY",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":44},"100568431","study-of-normal-intestinal-development-and-disease-in-premature-and-term-neonates-100568431","NCT06681129","Study of Normal Intestinal Development and Disease in Premature and Term Neonates","Study of Normal Intestinal Development and Disease in Premature and Term Neonates - a Pathway for the Study of Premature and Neonatal Intestinal Disorders Including the Roles of Nutrition, Microbes, and Cellular Physiology, and Diseases Including Necrotizing Enterocolitis","NiiCE","Inclusion Criteria:\n\n* Any neonate or infant through 2 years of age having intestinal surgery or intestinal biopsies from an esophogastroduodenoscopy (EGD) or colonoscopy.\n\nExclusion Criteria:\n\n* Children \\> 2 years of age.\n* Infants 0-2 years old not undergoing GI surgery or intestinal scope with biopsy procedure.","2 Years",{"count":91,"type":22},100,"Current research on early intestinal development is primarily performed in mouse models. While useful in many other ways, mouse models are not ideal for studying human intestine development as the timing of this process differs between the two species. Further, prior research has demonstrated that some proteins and pathways that are critical in human development have no clear role in mice.\n\nThis study aims to improve the overall understanding of critical aspects of intestinal development in humans. In addition, this study will investigate the impact of intestinal diseases that are found in the early stages of life such as necrotizing enterocolitis (NEC).",[94,95,28,96],"NEC","Necrotizing Enterocolitis","Human Development",[94,98,99,95],"Early Intestinal Development","Intestinal Intervention","2026-03-24",{"date":102,"type":36},"2026-03-27",{"date":104,"type":36},"2025-03-17",{"date":106,"type":22},"2034-12-31",{"name":108,"class":43},"Boston Children's Hospital",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":54,"phases":118,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":44},"100524716","phase-4-neuromuscular-blockade-comparison-for-gi-2-recovery-after-bowel-resection-100524716","NCT06112353","Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection","Sugammadex VS Neostigmine and Glycopyrrolate Reversal of Neuromuscular Relaxation For Time to Return of Bowel Function After Bowel Resection: Prospective, Randomized, Triple-blinded Clinical Trial For Quality Improvement","Inclusion Criteria:\n\n* Age 18 or older\n* Laparoscopic bowel resection surgery under general anesthesia with nondepolarizing neuromuscular blockade with rocuronium or vecuronium, and requiring inpatient admission\n\nExclusion Criteria:\n\n* Allergy to Rocuronium, Vecuronium, or Sugammadex\n* Bowel resection surgery requiring an ostomy\n* No severe valvulopathy, no systolic heart failure with reduced ejection fraction (HFrEF), no coronary artery disease with positive stress test for ischemic regional wall motion abnormality\n* No autoimmune pulmonary disease, no severe pulmonary fibrosis, no severe pulmonary hypertension, no COPD with requirement of home oxygen, no pulmonary cancer of primary or metastatic origin\n* Creatinine Clearance (CrCl) of less than 30\n* Pregnancy\n* Incapable of providing consent or understanding the research project",{"count":117,"type":22},128,[56],"The purpose of this research study is to see the outcome of Sugammadex versus Neostigmine with Glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (in hours) to first bowel movement and tolerance for solid food (GI-2 recovery) following bowel resection surgery",[28],[122,123,124,125,126],"Laparoscopic Bowel Resection","Sugammadex","Neostigmine","Glycopyrrolate","GI-2","2026-01-21",{"date":129,"type":36},"2026-01-23",{"date":131,"type":36},"2024-04-17",{"date":133,"type":22},"2026-07-31",{"name":135,"class":43},"University of California, Irvine",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":17,"sex":18,"minAge":143,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":54,"phases":146,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":44},"100601739","phase-3-a-study-to-evaluate-safety-and-efficacy-of-pbkm2502-100601739","NCT07114406","A Study to Evaluate Safety and Efficacy of PBK_M2502","A Prospective, Randomized, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of PBK_M2502","Inclusion Criteria:\n\n* Patients who is informed and give a consent in voluntary\n* Patients who is scheduled a esophagogastroduodenoscopy and colonoscopy\n* BMI 19≤and\\\u003C30\n\nExclusion Criteria:\n\n* Patients who participate in other interventional study or had participated within 30 days before screening\n* Pregnant or breast-feeding women who do not want to stop breast-feeding\n* Uncontrolled hypertension\n* Uncontrolled diabetes\n* Fluid or electrolyte (Na, K, Ca, Mg, chloride, bicarbonate) disturbance\n* HIV infection and\u002For chronic hepatitis B or C\n* Patients who has a difficulty to participate because of severe nausea or vomiting\n* History of colon surgery and abdominal surgery within 6 month; need an emergency surgery","19 Years",{"count":145,"type":22},110,[147],"PHASE3","This clinical trial was prospective, randomized, single-blind, 3-treatment arm, parallel treatment group, and active-controlled. , Multi-center, Phase 3 confirmatory clinical trial.",[28,150,151,62],"Colonic Diseases","Gastrointestinal Disease","2025-08-03",{"date":154,"type":36},"2025-08-11",{"date":156,"type":22},"2025-08",{"date":158,"type":22},"2026-11",{"name":160,"class":80},"Pharmbio Korea Co., Ltd.",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":169,"targetDuration":171,"studyType":23,"phases":4,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":44},"100581070","outcomes-of-outpatients-in-an-gut-microbiota-clinic-100581070","NCT06845527","Outcomes of Outpatients in an Gut Microbiota Clinic","Characteristics and Outcomes of Outpatients Referred to an Gut Microbiota Clinic","Microfec","Inclusion Criteria:\n\n* Age ≥18 years;\n* Patient attending the Gut Microbiota Clinic at Fondazione Policlinico Universitario \"A. Gemelli\" IRCCS;\n* Ability to provide informed consent for inclusion in the study;\n* Patient in possession of a gut microbiota test, performed as part of routine clinical practice upon medical request, no more than one month prior to the first visit.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years;\n* Severe psychiatric disorders;\n* Inability to provide informed conse",{"count":170,"type":22},400,"12 Months","The gut microbiota plays a crucial role in human health, influencing metabolism, immunity, and pathogen resistance. Research has linked microbiome dysbiosis to various intestinal and extra-intestinal disorders, prompting interest in therapeutic strategies like fecal microbiota transplantation (FMT), which is now standard for recurrent Clostridioides difficile infection and shows promise for other conditions.\n\nDespite its potential, the clinical integration of microbiome research remains limited due to biological complexity, lack of clinician awareness, and the absence of standardized guidelines. Meanwhile, patient demand for microbiome-based interventions is rising, leading some to seek non-scientific alternatives with potential health risks.\n\nSince 2016, the Gut Microbiota Clinic at Fondazione Policlinico Gemelli has provided personalized microbiota-based treatments, collaborating with specialists across disciplines. The clinic primarily serves patients with gastrointestinal and extra-intestinal disorders and employs a multidisciplinary approach.\n\nThis study aims to characterize the clinical and microbiological profiles of patients attending the clinic and establish a microbiological database. Primary and secondary endpoints include microbiota composition changes and clinical outcomes assessed through validated diagnostic tools.",[28],[175,176,177],"Gut Dysbiosis","Microbiome testing","Microbiome","2025-07-10",{"date":180,"type":36},"2025-07-15",{"date":182,"type":36},"2025-03-13",{"date":184,"type":22},"2027-03-10",{"name":186,"class":43},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":195,"enrollmentInfo":196,"targetDuration":198,"studyType":23,"phases":4,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":210,"locationsCount":44},"100591522","caspase-1-activity-il-1beta-and-il-18-in-patients-with-fmf-100591522","NCT06981520","Caspase-1 Activity, IL-1beta, and IL-18 in Patients With FMF","Effect of Caspase-1 Activity, IL-1beta, and IL-18 on Inflammation in the Mucosa of the Small Intestine of Patients With FMF","FMF","Inclusion Criteria:Age 18 years or older\n\nConfirmed diagnosis of Familial Mediterranean Fever (FMF) according to Tel-Hashomer clinical criteria and\u002For MEFV gene mutation analysis (for FMF group)\n\nUndergoing routine endoscopy with mucosal biopsy sampling\n\nAvailability of sufficient formalin-fixed paraffin-embedded (FFPE) tissue for immunohistochemical analysis\n\nFor controls: absence of systemic inflammatory or autoimmune disease -\n\nExclusion Criteria:History of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)\n\nCurrent use of immunosuppressive therapy (excluding colchicine)\n\nSevere infection, active malignancy, or other systemic disease affecting intestinal mucosa\n\nInadequate biopsy specimen quality for histopathological evaluation\n\n\\-","55 Years",{"count":197,"type":22},30,"8 Months","This study aims to investigate the intestinal mucosal expression of key inflammatory markers, namely Interleukin-1 (IL-1), Interleukin-18 (IL-18), and Caspase-1, in patients with Familial Mediterranean Fever (FMF). FMF is an autoinflammatory disorder characterized by recurrent episodes of fever and serosal inflammation. Recent studies suggest a possible role of intestinal immune activation in the disease pathogenesis, particularly through inflammasome-related cytokines. To better understand mucosal involvement in FMF, immunohistochemical staining for IL-1, IL-18, and Caspase-1 will be performed on intestinal biopsy samples obtained during routine endoscopic procedures. The staining intensity and distribution patterns will be evaluated and compared with age- and sex-matched healthy controls. The findings may help clarify mucosal inflammatory pathways involved in FMF and provide insight into novel therapeutic targets.",[201,28,202,203],"Familial Mediterranean Fever","Genetic Disease","Fever","2025-05-13",{"date":206,"type":36},"2025-05-20",{"date":178,"type":22},{"date":209,"type":22},"2026-01-19",{"name":211,"class":43},"Hitit University",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":220,"targetDuration":222,"studyType":23,"phases":4,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":4},"100529786","descripitive-patient-analysis-to-enable-risk-based-quality-improvement-measures-in-a-large-internal-medicine-group-practice-100529786","NCT06178302","DEscripitive Patient Analysis to Enable Risk-based Quality Improvement Measures in a lArge iNternal mediCIne grouP Practice","DEscripitive Patient Analysis to Enable Risk-based Quality Improvement Measures in a lArge iNternal mediCIne grouP Practice - The EMANCIPATE Study","EMANCIPATE","1. Female or male patients aged above 18 years diagnosed with chronic liver disease, undergo on-site endoscopy, suffer from atherosclerosis, heart failure, are diagnosed with abnormal serum thyroid-stimulating hormone (TSH) levels, either overt or latent hypo- or hyperthyroidism, or are diagnosed with solitary or multiple thyroid nodules.\n2. Routine laboratory results available within the last 3 months.\n3. Available imaging data within the last 3 months performed on site.",{"count":221,"type":22},1000,"10 Years","Background: Clinical trials often include patients from large hospitals or university clinics. Information on patients cared for at offices from statutory health insurance-accredited physicians represent evidence gaps.\n\nAims\u002FObjectives:\n\nThe present study has three aims: First, to systematically describe the patient population of a large group practice for internal medicine. Second, to identify high-risk patients using established risk scores. And third, to include routine imaging data to optimize patient management.\n\nMethods\u002FFacility Enrolling Participants: This is a prospective, observational study assessing patients' baseline characteristics, risk evaluation and integrating data from imaging test. The setting of the present study is a large group practice for internal medicine which consists of statutory health insurance-accredited physicians. Study participants will be included during daily routine, real-world clinical care and therefore represent all-comers fulfilling the inclusion criteria:\n\n1. Female or male patients aged above 18 years diagnosed with chronic liver disease, undergo on-site endoscopy, suffer from atherosclerosis, heart failure, are diagnosed with abnormal serum thyroid-stimulating hormone (TSH) levels, either overt or latent hypo- or hyperthyroidism, or are diagnosed with solitary or multiple thyroid nodules.\n2. Routine laboratory results available within the last 3 months.\n3. Available imaging data within the last 3 months performed on site. Perspective: The study is designed to evaluate the current situation and quality of health care in defined patient populations in the routine clinical setting of a large-scale public office. These data will provide a profound rationale to identify quality issues and limitations in our performance of guideline-conform treatment in routine patient care.",[225,226,227,228,28,229],"Liver Dysfunction","Thyroid","Atherosclerosis","Heart Failure","Heart Diseases","2025-05-05",{"date":232,"type":36},"2025-05-07",{"date":234,"type":22},"2025-12",{"date":236,"type":22},"2035-06",{"name":238,"class":43},"Imed19",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":17,"sex":18,"minAge":89,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":54,"phases":248,"briefSummary":250,"conditions":251,"keywords":256,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":268},"100455362","immune-responses-to-gluten-100455362","NCT05209568","Immune Responses to Gluten","Changes in Serum IL-2 Levels Following a Single Oral Dose of Gluten","Inclusion Criteria:\n\n1. On a gluten-free diet for ≥ 4 weeks\n2. Willing to consume gluten for research\n3. For the celiac disease arm, diagnosis confirmed by serology and\u002For histology\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Wheat allergy\n3. Type 1 diabetes\n4. BMI z-score \\\u003C -2\n5. History of more than minimal symptoms following gluten exposure on a gluten-free diet\n6. Comorbid condition that in the opinion of the investigator would interfere with study participation or would confound study results","101 Years",{"count":170,"type":22},[249],"NA","This is a study of immune responses after eating gluten powder in people with celiac disease and healthy controls.",[252,253,62,28,60,254,255],"Celiac Disease","Malabsorption Syndromes","Gluten Sensitivity","Celiac Disease in Children",[257,258,259],"gluten","cytokine","T cell immune response","2025-04-18",{"date":262,"type":36},"2025-04-23",{"date":264,"type":36},"2023-01-15",{"date":266,"type":22},"2029-09-30",{"name":108,"class":43},2]